Anti-HLA-G Purified

Anti-HLA-G Purified
Regulatory status
RUO
Antigen
HLA-G
Clone
MEM-G/2
Format
Purified
Reactivity
Human
Variant
0.1 mg
11-436-C100
In stock
170.00 USD

0.025 mg
11-436-C025
In stock
85.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD

0.1 mg
11-261-C100
In stock
85.00 USD
Product details
Description
Images
References
Isotype
Mouse IgG1
Specificity
The antibody MEM-G/2 recognizes an extracellular epitope on free heavy chain of all the HLA-G isoforms. HLA-G belongs to the MHC Class I molecules (MHC Class Ib; nonclassical) and it is expressed on the surface of trophoblast cells.
Application details
Western blotting: Recommended dilution 1-2 μg/ml.
Reactivity
Human
Immunogen
Bacterially expressed recombinant HLA-G heavy chain (denatured).
Concentration
1 mg/ml
Preparation
Purified by protein-A affinity chromatography.
Formulation
Phosphate buffered saline (PBS), pH 7.4, 15 mM sodium azide
Storage and handling
Store at 2-8°C. Do not freeze.
Exbio licence note
The product is intended For Research Use Only. Diagnostic or therapeutic applications are strictly forbidden. Products shall not be used for resale or transfer to third parties either as a stand-alone product or as a manufacture component of another product without written consent of EXBIO Praha, a.s. EXBIO Praha, a.s. will not be held responsible for patent infringement or any other violations of intellectual property rights that may occur with the use of the products. Orders for all products are accepted subject to the Term and Conditions available at www.exbio.cz. EXBIO, EXBIO Logo, and all other trademarks are property of EXBIO Praha, a.s.
Antigen description
Human leukocyte antigen G (HLA-G), belonging to MHC class I glycoproteins, plays important roles in both physiological and pathological immunotolerance. It gives an inhibitory signal to cytotoxic T cells, NK cells, monocytes, and some other immune cells. It also induces regulatory T cells and anti-inflammatory macrophages. HLA-G is important e.g. for maternal tolerance to the fetus, and for immunomodulation in particular adult tissues, such as in cornea, pancreatic islets, thymus and other. On the other hand, it is expressed in many solid and hematologic malignancies, where it contributes to evasion of the immune surveillance. HLA-G expression pattern in cancer is an important prognostic factor regarding a poor clinical outcome. Unlike most other MHC glycoproteins, HLA-G acts as an immune checkpoint molecule rather than as an antigen presenting molecule. It concerns both transmembrane and soluble HLA-G isoforms. Among other, HLA-G can promote Th2 immunological response and downregulate Th1 immunological response. For its benefits regarding allograft tolerance, including embryo implantation, soluble HLA-G (sHLA-G) can be used as a marker of developmental potential of embryos during the process of in vitro fertilization. Similarly, sHLA-G concentrations in maternal serum are decreased in preeclampsia. Transplanted patients with increased sHLA-G serum levels have improved allograft acceptance. On the other hand, increased sHLA-G can also indicate presence of malignant (sometimes also of benign) tumor cells. Another important topic is induction of HLA-G expression (sometimes associated with shedding of HLA-G from the cell surface) by some anti-cancer or anti-viral therapies, which can weaken the therapy effect. Monitoring of HLA-G in patients thus has a wide usage.
Entrez Gene ID 3135
UniProt ID P17693
11-436_IHC
Immunohistochemistry staining of kidney allograft biopsy (paraffin-embedded sections) with anti-human HLA-G (MEM-G/2).
11-436_WB
Western blotting analysis of human HLA-G using mouse monoclonal antibody MEM-G/2 on lysates of JEG-3 cell line and LNCaP cell line (negative control) under reducing and non-reducing conditions. Nitrocellulose membrane was probed with 2 µg/ml of mouse monoclonal antibody anti-HLA-G followed by IRDye800-conjugated anti-mouse secondary antibody. HLA-G was detected at approximately 40 kDa.
11-436 WB
Western blotting analysis of HLA-G in LCL-HLA-G transfectants using anti-HLA-G (MEM-G/2).

General references:

Creput C, Durrbach A, Menier C, Guettier C, Samuel D, Dausset J, Charpentier B, Carosella ED, Rouas-Freiss N. Human leukocyte antigen-G (HLA-G) expression in biliary epithelial cells is associated with allograft acceptance in liver-kidney transplantation. J Hepatol. 2003 39(4):587-94.
PubMed
Menier C, Saez B, Horejsi V, Martinozzi S, Krawice-Radanne I, Bruel S, LeDanff C, Reboul M, Hilgert I, Rabreau M, Larrad ML, Pla M, Carosella ED, Rouas-Freiss N: Characterization of monoclonal antibodies recognizing HLA-G or HLA-E: new tools to analyze the expression of nonclassical HLA class I molecules. Hum Immunol. 2003 64(3):315-26.
PubMed
Lin A, Yan WH: Heterogeneity of HLA-G expression in cancers: Facing the challenges. Front Immunol. 2018 Sep 27;9:2164.
PubMed
Hunt JS, Langat DK, McIntire RH, Morales PJ: The role of HLA-G in human pregnancy. Reprod Biol Endocrinol. 2006;4 Suppl 1(Suppl 1):S10.
PubMed
Xu HH, Yan WH, Lin A: The role of HLA-G in human papillomavirus infections and cervical carcinogenesis. Front Immunol. 2020 Jun 25;11:1349.
PubMed
Castelli EC, de Almeida BS, Muniz YC, Silva NS, Passos MR, Souza AS, Page AE, Dyble M, Smith D, Aguileta G, Bertranpetit J, Migliano AB, Duarte YA, Scliar MO, Wang J, Passos-Bueno MR, Naslavsky MS, Zatz M, Mendes CT, Donadi EA: HLA-G genetic diversity and evolutive aspects in worldwide populations. Sci Rep. 2021 Nov 29;11(1):23070.
PubMed
Curigliano G, Criscitiello C, Gelao L, Goldhirsch A: Molecular pathways: Human leukocyte antigen G (HLA-G). Clin Cancer Res. 2013 Oct 15;19(20):5564-71.
PubMed

Product specific references:

Le Discorde M, Moreau P, Sabatier P, Legeais JM, Carosella ED: Expression of HLA-G in human cornea, an immune-privileged tissue. Hum Immunol. 2003 Nov;64(11):1039-44.
PubMed
Poláková K, Bandzuchová E, Hofmeister V, Weiss EH, Hutter H, Russ G: Binding analysis of HLA-G specific antibodies to hematopoietic cells isolated from leukemia patients. Neoplasma. 2003;50(5):331-8.
PubMed
Lazana I, Zoudiari A, Kokkinou D, Themeli M, Liga M, Papadaki H, Papachristou D, Spyridonidis A: Identification of a novel HLA-G+ regulatory population in blood: expansion after allogeneic transplantation and de novo HLA-G expression at graft-versus-host disease sites. Haematologica. 2012 Sep;97(9):1338-47
PubMed
Boyson JE, Erskine R, Whitman MC, Chiu M, Lau JM, Koopman LA, Valter MM, Angelisova P, Horejsi V, Strominger JL: Disulfide bond-mediated dimerization of HLA-G on the cell surface. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16180-5.
PubMed
Creput C, Le Friec G, Bahri R, Amiot L, Charpentier B, Carosella E, Rouas-Freiss N, Durrbach A: Detection of HLA-G in serum and graft biopsy associated with fewer acute rejections following combined liver-kidney transplantation: Possible implications for monitoring patients. Hum Immunol. 2003 Nov;64(11):1033-8.
PubMed
Zhang X, Lin A, Han QY, Zhang JG, Chen QY, Ye YH, Zhou WJ, Xu HH, Gan J, Yan WH: Intratumor heterogeneity of HLA-G expression in cancer lesions. Front Immunol. 2020 Nov 19;11:565759.
PubMed
Variant
0.1 mg
11-436-C100
In stock
170.00 USD

0.025 mg
11-436-C025
In stock
85.00 USD
Variant
0.1 mg
11-261-C100
In stock
170.00 USD

0.1 mg
11-261-C100
In stock
85.00 USD